Literature DB >> 10674005

Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: is it standard practice or still a subject for study?

V H Bramwell, K I Pritchard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10674005     DOI： 10.1016/s0959-8049(99)00204-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  3 in total

1.  A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12).

Authors:  V H C Bramwell; K I Pritchard; D Tu; K Tonkin; H Vachhrajani; T A Vandenberg; J Robert; A Arnold; S E O'Reilly; B Graham; L Shepherd
Journal:  Ann Oncol       Date:  2009-07-23       Impact factor: 32.976

2.  Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial.

Authors:  C Focan; M Beauduin; E Salamon; J de Greve; G de Wasch; J P Lobelle; F Majois; A Tagnon; J Tytgat; S van Belle; R Vandervellen; A Vindevoghel
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

Review 3.  Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal women.

Authors:  Kathleen Pritchard
Journal:  Breast Cancer Res       Date:  2005-02-11       Impact factor: 6.466
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.